AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RNA
  4. [Form 4] Avidity Biosciences, Inc. Insider Trading Activity

[Form 4] Avidity Biosciences, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Steven George Hughes, Chief Medical Officer of Avidity Biosciences (RNA), reported multiple option exercises and subsequent sales on 08/06/2025. He exercised options with strike prices of $15.96, $6.57, $22.47, and $10.16, acquiring 11,283, 12,334, 6,167, and 17,667 shares respectively. Several of the acquired shares were sold the same day under a Rule 10b5-1 trading plan adopted June 12, 2024.

Sales were reported at a weighted-average price of $42.7373 with transaction prices ranging from $40.15 to $46.44. The filing shows the reporting person鈥檚 direct beneficial ownership of common stock following the transactions as 38,867 shares. The Form 4 also includes grant dates and monthly vesting schedules for each option grant.

Steven George Hughes, Direttore medico di Avidity Biosciences (RNA), ha comunicato l'esercizio di pi霉 opzioni e le vendite successive in data 6 agosto 2025. Ha esercitato opzioni con prezzi di esercizio di $15.96, $6.57, $22.47 e $10.16, acquisendo rispettivamente 11,283, 12,334, 6,167 e 17,667 azioni. Diverse delle azioni acquisite sono state vendute lo stesso giorno nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 12 giugno 2024.

Le vendite sono state riportate a un prezzo medio ponderato di $42.7373, con prezzi per transazione compresi tra $40.15 e $46.44. Il filing indica la propriet脿 diretta beneficiaria di azioni ordinarie della persona segnalante, dopo le transazioni, pari a 38,867 azioni. Il Modulo 4 include inoltre le date di assegnazione e i piani di maturazione mensili per ciascun grant di opzioni.

Steven George Hughes, Director m茅dico de Avidity Biosciences (RNA), inform贸 la ejecuci贸n de varias opciones y ventas subsecuentes el 6 de agosto de 2025. Ejerci贸 opciones con precios de ejercicio de $15.96, $6.57, $22.47 y $10.16, adquiriendo 11,283, 12,334, 6,167 y 17,667 acciones, respectivamente. Varias de las acciones adquiridas se vendieron el mismo d铆a bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 12 de junio de 2024.

Las ventas se reportaron a un precio promedio ponderado de $42.7373, con precios por transacci贸n que oscilaron entre $40.15 y $46.44. El informe muestra la propiedad directa beneficiaria de acciones ordinarias de la persona informante tras las transacciones en 38,867 acciones. El Formulario 4 tambi茅n incluye las fechas de concesi贸n y los calendarios de consolidaci贸n mensuales para cada otorgamiento de opciones.

Steven George Hughes電� Avidity Biosciences(RNA)鞚� 斓滉碃鞚橂毂呾瀯鞛愲靹� 2025雲� 8鞗� 6鞚� 鞐煬 欤检嫕毵れ垬靹犿儩甓� 頄夓偓鞕� 鞚错泟 毵る弰毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 頄夓偓臧�瓴╈澊 $15.96, $6.57, $22.47, $10.16鞚� 鞓奠厴鞚� 頄夓偓頃橃棳 臧侁皝 11,283, 12,334, 6,167, 17,667欤检潣 欤检嫕鞚� 旆摑頄堨姷雼堧嫟. 旆摑頃� 欤检嫕 欷� 鞚茧秬電� 2024雲� 6鞗� 12鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 臧欖潃 雮� 毵る弰霅橃棃鞀惦媹雼�.

毵る弰電� 瓯半灅氤� 臧�瓴� 氩旍渼臧� $40.15鞐愳劀 $46.44 靷澊鞓�鞙茧┌, 臧�欷戫弶攴� 臧�瓴╈潃 $42.7373搿� 氤搓碃霅橃棃鞀惦媹雼�. 鞝滌稖靹滊電� 瓯半灅 頉� 氤搓碃鞚胳潣 氤错喌欤� 歆侅爲 氤挫湢臧� 38,867欤检瀯鞚� 雮橅儉雰呺媹雼�. 霕愴暅 Form 4鞐愲姅 臧� 鞓奠厴 攵�鞐潣 攵�鞐澕瓿� 鞗旊硠 氩犾姢韺�(甓岆Μ頇曥爼) 鞚检爼鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.

Steven George Hughes, Directeur m茅dical d'Avidity Biosciences (RNA), a d茅clar茅 plusieurs exercices d'options et ventes subs茅quentes le 6 ao没t 2025. Il a exerc茅 des options avec des prix d'exercice de $15.96, $6.57, $22.47 et $10.16, acqu茅rant respectivement 11,283, 12,334, 6,167 et 17,667 actions. Plusieurs des actions acquises ont 茅t茅 vendues le jour m锚me dans le cadre d'un plan de n茅gociation Rule 10b5-1 adopt茅 le 12 juin 2024.

Les ventes ont 茅t茅 d茅clar茅es 脿 un prix moyen pond茅r茅 de $42.7373, avec des prix par transaction allant de $40.15 脿 $46.44. Le d茅p么t indique la d茅tention effective directe d'actions ordinaires par la personne d茅clarant, apr猫s les transactions, 脿 38,867 actions. Le Formulaire 4 inclut 茅galement les dates d'attribution et les calendriers d'acquisition mensuels pour chaque attribution d'options.

Steven George Hughes, Chief Medical Officer (medizinischer Leiter) von Avidity Biosciences (RNA), meldete am 6. August 2025 mehrere Aus眉bungen von Optionen und anschlie脽ende Verk盲ufe. Er 眉bte Optionen mit Aus眉bungspreisen von $15.96, $6.57, $22.47 und $10.16 aus und erwarb jeweils 11,283, 12,334, 6,167 und 17,667 Aktien. Mehrere der erworbenen Aktien wurden am selben Tag im Rahmen eines Rule-10b5-1-Handelsplans verkauft, der am 12. Juni 2024 angenommen wurde.

Die Verk盲ufe wurden zu einem gewichteten Durchschnittspreis von $42.7373 gemeldet, mit Einzeltransaktionspreisen zwischen $40.15 und $46.44. Die Einreichung weist das unmittelbare wirtschaftliche Eigentum der meldenden Person an Stammaktien nach den Transaktionen mit 38,867 Aktien aus. Das Formular 4 enth盲lt zudem die Zuteilungsdaten und monatlichen Vesting鈥慞l盲ne f眉r jede Optionszuteilung.

Positive
  • Sales were executed under a Rule 10b5-1 trading plan adopted June 12, 2024, which documents pre-arranged, rule-compliant dispositions.
  • Multiple option grants and vesting schedules are disclosed (grant dates and monthly vesting installments are provided for each option).
Negative
  • Multiple sizeable sales were reported on 08/06/2025 (individual sale entries include 11,283; 12,334; 6,167; 17,667; and 33,983 shares) which materially reduce the reporting person鈥檚 immediate shareholding.
  • Direct beneficial ownership of common stock after the transactions is shown as 38,867 shares, a notable post-transaction balance disclosed in the filing.

Insights

TL;DR: Insider exercised options and sold shares under a 10b5-1 plan; weighted-average sale price $42.7373 recorded.

The reporter exercised four option tranches on 08/06/2025 acquiring 11,283; 12,334; 6,167; and 17,667 shares at strikes of $15.96, $6.57, $22.47, and $10.16 respectively. Multiple sales occurred the same day under a Rule 10b5-1 plan with a reported weighted-average sale price of $42.7373 and per-share sale prices between $40.15 and $46.44. Post-transaction direct beneficial ownership of common stock is shown as 38,867 shares. These transactions are material to monitoring insider liquidity but are documented as plan-based executions.

TL;DR: Transactions were executed pursuant to a documented Rule 10b5-1 plan adopted June 12, 2024; vesting schedules and grant dates are included.

The Form 4 discloses that the sales were effected under a Rule 10b5-1 trading plan and provides explicit vesting schedules for each option grant (grant dates: 02/14/2022; 09/11/2023; 01/20/2023; 01/20/2024). The filing is signed by an attorney-in-fact and includes an explanation of price ranges and the reporting person鈥檚 undertaking to provide detailed sales data on request. From a governance standpoint, the transaction is properly documented and accompanied by required explanatory notes.

Steven George Hughes, Direttore medico di Avidity Biosciences (RNA), ha comunicato l'esercizio di pi霉 opzioni e le vendite successive in data 6 agosto 2025. Ha esercitato opzioni con prezzi di esercizio di $15.96, $6.57, $22.47 e $10.16, acquisendo rispettivamente 11,283, 12,334, 6,167 e 17,667 azioni. Diverse delle azioni acquisite sono state vendute lo stesso giorno nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 12 giugno 2024.

Le vendite sono state riportate a un prezzo medio ponderato di $42.7373, con prezzi per transazione compresi tra $40.15 e $46.44. Il filing indica la propriet脿 diretta beneficiaria di azioni ordinarie della persona segnalante, dopo le transazioni, pari a 38,867 azioni. Il Modulo 4 include inoltre le date di assegnazione e i piani di maturazione mensili per ciascun grant di opzioni.

Steven George Hughes, Director m茅dico de Avidity Biosciences (RNA), inform贸 la ejecuci贸n de varias opciones y ventas subsecuentes el 6 de agosto de 2025. Ejerci贸 opciones con precios de ejercicio de $15.96, $6.57, $22.47 y $10.16, adquiriendo 11,283, 12,334, 6,167 y 17,667 acciones, respectivamente. Varias de las acciones adquiridas se vendieron el mismo d铆a bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 12 de junio de 2024.

Las ventas se reportaron a un precio promedio ponderado de $42.7373, con precios por transacci贸n que oscilaron entre $40.15 y $46.44. El informe muestra la propiedad directa beneficiaria de acciones ordinarias de la persona informante tras las transacciones en 38,867 acciones. El Formulario 4 tambi茅n incluye las fechas de concesi贸n y los calendarios de consolidaci贸n mensuales para cada otorgamiento de opciones.

Steven George Hughes電� Avidity Biosciences(RNA)鞚� 斓滉碃鞚橂毂呾瀯鞛愲靹� 2025雲� 8鞗� 6鞚� 鞐煬 欤检嫕毵れ垬靹犿儩甓� 頄夓偓鞕� 鞚错泟 毵る弰毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 頄夓偓臧�瓴╈澊 $15.96, $6.57, $22.47, $10.16鞚� 鞓奠厴鞚� 頄夓偓頃橃棳 臧侁皝 11,283, 12,334, 6,167, 17,667欤检潣 欤检嫕鞚� 旆摑頄堨姷雼堧嫟. 旆摑頃� 欤检嫕 欷� 鞚茧秬電� 2024雲� 6鞗� 12鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 臧欖潃 雮� 毵る弰霅橃棃鞀惦媹雼�.

毵る弰電� 瓯半灅氤� 臧�瓴� 氩旍渼臧� $40.15鞐愳劀 $46.44 靷澊鞓�鞙茧┌, 臧�欷戫弶攴� 臧�瓴╈潃 $42.7373搿� 氤搓碃霅橃棃鞀惦媹雼�. 鞝滌稖靹滊電� 瓯半灅 頉� 氤搓碃鞚胳潣 氤错喌欤� 歆侅爲 氤挫湢臧� 38,867欤检瀯鞚� 雮橅儉雰呺媹雼�. 霕愴暅 Form 4鞐愲姅 臧� 鞓奠厴 攵�鞐潣 攵�鞐澕瓿� 鞗旊硠 氩犾姢韺�(甓岆Μ頇曥爼) 鞚检爼鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.

Steven George Hughes, Directeur m茅dical d'Avidity Biosciences (RNA), a d茅clar茅 plusieurs exercices d'options et ventes subs茅quentes le 6 ao没t 2025. Il a exerc茅 des options avec des prix d'exercice de $15.96, $6.57, $22.47 et $10.16, acqu茅rant respectivement 11,283, 12,334, 6,167 et 17,667 actions. Plusieurs des actions acquises ont 茅t茅 vendues le jour m锚me dans le cadre d'un plan de n茅gociation Rule 10b5-1 adopt茅 le 12 juin 2024.

Les ventes ont 茅t茅 d茅clar茅es 脿 un prix moyen pond茅r茅 de $42.7373, avec des prix par transaction allant de $40.15 脿 $46.44. Le d茅p么t indique la d茅tention effective directe d'actions ordinaires par la personne d茅clarant, apr猫s les transactions, 脿 38,867 actions. Le Formulaire 4 inclut 茅galement les dates d'attribution et les calendriers d'acquisition mensuels pour chaque attribution d'options.

Steven George Hughes, Chief Medical Officer (medizinischer Leiter) von Avidity Biosciences (RNA), meldete am 6. August 2025 mehrere Aus眉bungen von Optionen und anschlie脽ende Verk盲ufe. Er 眉bte Optionen mit Aus眉bungspreisen von $15.96, $6.57, $22.47 und $10.16 aus und erwarb jeweils 11,283, 12,334, 6,167 und 17,667 Aktien. Mehrere der erworbenen Aktien wurden am selben Tag im Rahmen eines Rule-10b5-1-Handelsplans verkauft, der am 12. Juni 2024 angenommen wurde.

Die Verk盲ufe wurden zu einem gewichteten Durchschnittspreis von $42.7373 gemeldet, mit Einzeltransaktionspreisen zwischen $40.15 und $46.44. Die Einreichung weist das unmittelbare wirtschaftliche Eigentum der meldenden Person an Stammaktien nach den Transaktionen mit 38,867 Aktien aus. Das Formular 4 enth盲lt zudem die Zuteilungsdaten und monatlichen Vesting鈥慞l盲ne f眉r jede Optionszuteilung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hughes Steven George
(Last) (First) (Middle)
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/06/2025 M(1) 11,283 A $15.96 84,133 D
Common Stock 08/06/2025 S(1) 11,283 D $42.7373(2) 72,850 D
Common Stock 08/06/2025 M(1) 12,334 A $6.57 85,184 D
Common Stock 08/06/2025 S(1) 12,334 D $42.7373(2) 72,850 D
Common Stock 08/06/2025 M(1) 6,167 A $22.47 79,017 D
Common Stock 08/06/2025 S(1) 6,167 D $42.7373(2) 72,850 D
Common Stock 08/06/2025 M(1) 17,667 A $10.16 90,517 D
Common Stock 08/06/2025 S(1) 17,667 D $42.7373(2) 72,850 D
Common Stock 08/06/2025 S(1) 33,983 D $42.7373(2) 38,867 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $15.96 08/06/2025 M(1) 11,283 (3) 02/13/2032 Common Stock 11,283 $0 73,342 D
Stock Option (Right to Buy) $6.57 08/06/2025 M(1) 12,334 (4) 09/10/2033 Common Stock 12,334 $0 52,417 D
Stock Option (Right to Buy) $22.47 08/06/2025 M(1) 6,167 (5) 01/19/2033 Common Stock 6,167 $0 74,000 D
Stock Option (Right to Buy) $10.16 08/06/2025 M(1) 17,667 (6) 01/19/2034 Common Stock 17,667 $0 75,083 D
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. This option was granted on February 14, 2022 and vests in equal installments of 5,652 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on February 14, 2026.
4. This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.
5. This option was granted on January 20, 2023 and vests in equal installments of 3,083 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027.
6. This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.
Remarks:
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Avidity Biosciences (RNA) insider Steven Hughes report on the Form 4?

The Form 4 reports option exercises and multiple sales on 08/06/2025, including exercises of options and sales executed under a Rule 10b5-1 plan.

How many shares were acquired by exercise and at what strike prices?

Options exercised acquired 11,283 shares at $15.96, 12,334 at $6.57, 6,167 at $22.47, and 17,667 at $10.16.

At what price were the insider sales executed for RNA?

Sales were reported at a weighted-average price of $42.7373, with prices ranging from $40.15 to $46.44.

What is Steven Hughes鈥� beneficial ownership after the reported transactions?

The Form 4 indicates direct beneficial ownership of 38,867 common shares following the reported transactions.

When was the 10b5-1 plan that governed these sales adopted?

The explanatory note states the Rule 10b5-1 trading plan was adopted on June 12, 2024.
Stock RNA logo
Avidity Biosciences, Inc.

NASDAQ:RNA

RNA Rankings

#1253 Ranked by Market Cap
N/A Ranked by Dividends

RNA Latest News

Aug 27, 2025
Avidity Biosciences to Participate in Upcoming Investor Conferences
Aug 7, 2025
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Jul 28, 2025
Avidity Biosciences Announces Completion of Enrollment for HARBOR鈩�, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
Jul 23, 2025
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Jun 11, 2025
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE鈩� Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

RNA Latest SEC Filings

Aug 22, 2025
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity
Aug 15, 2025
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity
Aug 15, 2025
[144] Avidity Biosciences, Inc. SEC Filing
Aug 15, 2025
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity
Aug 15, 2025
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity

RNA Stock Data

5.82B
119.96M
4.79%
107.43%
12.6%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO